News tagged with hydroxyurea
Hydroxycarbamide
Hydroxycarbamide (INN) or hydroxyurea (brand names include Hydrea and Droxia) is an antineoplastic drug, first synthesized in 1869, used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocythemia. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
'Half-match' bone marrow transplants wipe out sickle cell disease in selected patients
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, ...
Medical research
Sep 20, 2012 |
not rated yet |
0
|
Thalidomide analog appears worthy opponent of sickle cell disease
A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.
Medical research
Jul 18, 2011 |
5 / 5 (1) |
0
|
Sickle cell anemia drug safe and effective for infants and toddlers, adds treatment option
New research shows a drug commonly used to treat sickle cell anemia in adults reduces bouts of acute pain and a pneumonia-like illness, cuts hospitalization time and eases other symptoms of the disease in young patients. ...
Medications
May 12, 2011 |
5 / 5 (1) |
0
|
Nitric oxide impacts source of sickle cell pain crisis
Nitric oxide gas appears to directly impact the source of the classic, disabling pain crises of sickle cell disease, Georgia Health Sciences University researchers report.
Medical research
May 09, 2011 |
4 / 5 (1) |
0
|
ASH: More intense treatment beneficial in polycythemia vera
(HealthDay)—For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of less than 45 percent correlates with a significantly lower rate of cardiovascular death and major ...
Diseases, Conditions, Syndromes
Dec 10, 2012 |
not rated yet |
0
Anti-sickling therapies should be focus for sickle cell science
Pain is an undeniable focal point for patients with sickle cell disease but it's not the best focus for drug development, says one of the dying breed of physicians specializing in the condition.
Medical research
Apr 17, 2013 |
not rated yet |
0
A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events
In the first randomized clinical trial assessing the proper target hematocrit level, or percentage of red blood cells that should be maintained in patients with polycythemia vera (PV), researchers have concluded that the ...
Medical research
Dec 09, 2012 |
not rated yet |
0
